The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Filter
Locations
Result types
Type of company
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
Lock keywords
Exclude keywords
Optional keywords
San Diego, United States
11-50 Employees
2016
Qureator’s Microphysiological Systems (MPS) known as Curiochips , are designed for recapitulating the complexity of tissue microenvironments, thus providing ideal microscale 3D cell culture conditions for a variety of applications in biomedical research. Qureator has offices in San Diego, CA and Seoul, South Korea. Qureator’s Microphysiological Systems (MPS) known as Curiochips, are designed for recapitulating the complexity of tissue microenvironments, thus providing ideal microscale 3D cell culture conditions for a variety of applications in biomedical research.
+
Featured
Organ-on-a-chip | About Qureator’s Microphysiological Systems
... Our organ-on-a-chip are designed on the “ARCH” principle – Adoptability, Reproducibility, Customizability, and High-Throughput. ...
Oakland, United States
1-10 Employees
2018
We're creating engineered tissues to replace animal studies and save lives. Join us at the Forefront of Tissue Engineering & Regenerative Medicine. Animal experimentation is both controversial and unreliable in providing human-relevant results. But traditional 2D cell culture of human cells fails to capture the complexity of the 3D cellular microenvironment. Made of living human cells, our vascular Blood Vessel Mimics (BVMs) are already being used for medical device testing.
+
Featured
Engineered Tissue | Frontier Bio
... Frontier Bio aims to disrupt animal testing and save lives with engineered tissues using cutting-edge 3D bioprinting, organ-on-a-chip, and organoid technology. ...
East Hertfordshire, United Kingdom
11-50 Employees
2009
We are a close-knit team of passionate scientists, engineers and creative thinkers, all working together towards our shared goal – a future where drugs are discovered more quickly, brought to patients more cost-effectively, and through the use of less animal experimentation. We are innovators, creating cutting-edge, high-tech solutions that contribute to the development of new treatments to improve the lives of patients while reducing the need for animal testing. We are passionate about our technology and we know that CN Bio’s success depends on it being widely used. We are one team, listening and accepting, and always treating each other with respect and fairness, knowing that together we can achieve more. We are growing and evolving, constantly learning and pushing the boundaries of science and of what we can achieve. We are an organ-on-a-chip company that enables you to generate human-specific efficacy and safety data with pioneering PhysioMimix® single- and multi-organ solutions. Day to day our cohesive team design, manufacture, promote, and support organ-on-a-chip solutions that enable our customers to do something incredible – recreate three-dimensional human organs and tissues in the laboratory to better understand human physiology, disease, and the effectiveness of new drugs. Dharaminder is responsible for leading research projects within the company, often acting as the glue connecting the product development and assay development teams.
+
Featured
CN Bio | Predictive Organ-on-a-chip Drug Discovery Models
... CN Bio is a world leading organ-on-a-chip company. We empower you to transform drug discovery with our predictive human organ models. ...
London, United Kingdom
1-10 Employees
The UK Organ-on-a-Chip Technologies Network was established in 2018 to represent the UK community of scientists, industrialists, clinicians, funders and regulators working in the area of organ-on-a-chip technology. The network continues to operate as a forum for members to collaborate, share information, showcase their research activity and support one another. Many universities, have now established research centres in this multidisciplinary field such as the Centre for Predictive in vitro Models at Queen Mary University of London. Organ-chip research across the UK continues to expand in order to deliver the full potential of organ-on-a-chip technology.
+
Featured
Organ-on-a-Chip Technologies Network
... The UK Organ-on-a-Chip Technologies Network was funded by the MRC, EPSRC and BBSRC via the Technology Touching Life initiative, and designed to capture, inspire and grow UK research activity in the Organ-on-a-Chip research field. ...
Boston, United States
51-100 Employees
2013
By leveraging 21st century technologies, we are able to overcome these limitations with living human in vitro models that empower researchers to explore the biological mechanisms of health and disease. Since our inception, we have been focused on delivering exceptional science across multiple organs and applications. Jim Corbett has served as a leader of successful international businesses across diverse sectors, including biotechnology, medical imaging, analytical instruments and in vitro diagnostics. Ingber has authored more than 500 publications and over 160 issued or pending patents, founded 5 companies, and has been a guest speaker at more than 550 events internationally. Daniel Levner is the Chief Technology Officer at Emulate. A serial deep-tech entrepreneur, Levner co-founded Emulate and brings to it extensive experience in biological and engineering technology development and commercialization. Prior to joining Emulate, Kantor was Chief Financial Officer for Gemini Bioproducts, a private equity sponsored provider of cell culture media, sera and reagents, located in Northern California. Lorna additionally provides scientific supervision for the Emulate R&D and Services teams while also serving as the company’s European leader.
+
Featured
Organ-on-a-Chip Contract Research Services
... We offer a diverse portfolio of Organ-on-a-Chip compound testing services to help advance your drug development programs. ...
Berlin, Germany
11-50 Employees
2008
Surflay Nanotec focuses on functional surfaces, nanoscale coatings, polymers and microsensors. We develop novel membrane technologies together with our partners from the water industry. Surflay can support agriculture with innovative encapsulation techniques for pesticides, herbicides or fungicides. WhisperSense — an innovative device to monitor protein interactions / Nano-coater — easy way to coat your surface. Water is a valuable commodity, especially in times of drought and in areas with low water resources. In addition, the manufacturing industry in many industries requires thousands of cubic meters of fresh water, which must then be purified again. On the one hand, farmers have to work as productively and economically as possible, and on the other hand, they are required to produce in an ecologically sustainable way.
+
Featured
Microsensors | Surflay Nanotec
... organ-on-a-chip ...
Schlieren, Switzerland
11-50 Employees
2009
InSphero is the only 3D in vitro model company with the platform and expertise to modernize drug discovery in a way that empowers researchers to reach their full potential. InSphero’s goal is to inspire the next generation of breakthrough therapies through customer centricity, commitment to innovation, and the model of excellence. InSphero is challenging the status quo and working to make 3D in vitro platforms accessible to researchers everywhere. InSphero was founded in 2009 as an official spin-off from the Swiss Federal Institute of Technology – ETH Zürich. InSphero's Liver Disease team has published a groundbreaking peer-reviewed paper in Nature's Scientific Reports, challenging the limitations of in vitro models in MASH Drug Discovery. We are challenging the status quo, enabling the transition to alternatives to animal testing, and working to make human tissue 3D in vitro models accessible to researchers everywhere. We are the only 3D in vitro technology company providing up to 384 uniform cell culture models in an automation-compatible plate format ready for industry application. As our discovery partner, InSphero gives us immediate access to new 3D cell culture in vitro technologies, such as organ-on-a-chip systems, that provide deep mechanistic insights into complex diseases.
+
Featured
About InSphero - Pioneering 3D cell-based technology
... About InSphero: Advancing drug discovery leveraging the power of 3D cell-based technology and organ-on-a-chip technologies and platforms. ...
Paris, France
1-10 Employees
2017
We distribute our products worldwide, ensuring researchers and scientists across the globe have access to the high-quality microfluidics tools they need. IF YOU'RE HERE, IT'S BECAUSE YOU WANT TO KNOW WHO WE ARE. Darwin Microfluidics' mission is to make microfluidics easier for researchers around the world. In concrete terms, we offer a selection of truly useful products, carefully chosen by our microfluidics experts. Our team stays updated on latest microfluidics advancements to provide the best solutions. We adapt and evolve with the changing world of microfluidics, constantly updating our product range to meet current and future needs. We have microfluidics experts who understand the intricacies of the field, as well as customer service professionals who are committed to making your experience with us as smooth as possible. At Darwin, we believe in fostering partnerships, not transactions.
+
Featured
Organ-on-a-Chip - Cross-flow membrane w/ Open Chamber- Mini Luer
... This open version of Fluidic 653 Organ-on-a-Chip features two distinct culture chambers, accessible via multiple inlets and outlets, allowing co-culture of various cell types within two separate compartments divided by a permeable membrane. It has an open top for easy access to the upper ...
Santiago de Compostela, Spain
1-10 Employees
2020
Circular economy Industry 4.0 Sensors and production control. Either you provide the design or we help with it. Based on the description you provided, our technical team will produce the most appropriate configuration. Avoiding to make a prototype allows us to drastically reduce the production time.
+
Featured
BFlow | Organ on a chip systems and microfluidic solutions
... BFlow is a complete organ-on-a-chip systems and microfluidicsolutions for smart factories, biotech and lifeSciences, and ecology. ...
Le Kremlin-Bicêtre, France
11-50 Employees
2005
Fluigent is an international company which develops, manufactures and supports the most advanced fluid control systems available for microfluidics. Whether your application is with droplets, cell biology, particle studies, or in other research areas, we have the expertise and knowledge to provide the most cost-effective and technically advanced solutions to your fluid control needs. The microfluidic laboratories and industry were struggling to perform their research and develop equipment to the level and precision required in terms of fluid control. As a result there was a need for faster, more stable and precise technology for fluid handling at the microscale. Traditional syringe or peristaltic pumps are struggling to deliver this level of performance and could not meet the market needs.
+
Featured
Microfluidic pressure control for organ-on-a-chip applications: A comprehensive guide
... Essential definitions, advantages, and disadvantages of different pressure control technologies for organ on a chip applications. ...
Technologies which have been searched by others and may be interesting for you:
Some interesting numbers and facts about the results you have just received for Organ-on-a-Chip
| Country with most fitting companies | United States |
| Amount of fitting manufacturers | 25 |
| Amount of suitable service providers | 22 |
| Average amount of employees | 11-50 |
| Oldest suiting company | 2005 |
| Youngest suiting company | 2020 |
An Organ-on-a-Chip is a microfluidic cell culture device that simulates the activities, mechanics, and physiological responses of entire organs and organ systems. This innovative technology employs a network of tiny channels and compartments, constructed using clear, flexible polymers. These compartments house living cells and tissues that mimic the structure and function of human organs, such as the heart, lungs, liver, and kidneys. The primary goal of Organ-on-a-Chip technology is to replicate human organ responses to drugs and various chemical substances more accurately than traditional cell culture and animal models. This breakthrough has the potential to revolutionize the fields of pharmaceutical development and biomedical research, offering a more efficient and ethical approach to drug testing and disease modeling. By providing a more accurate human physiological environment, Organ-on-a-Chip can lead to significant advancements in personalized medicine, enabling researchers to tailor treatments to individual genetic makeups. Furthermore, this technology paves the way for reducing the reliance on animal testing, aligning with growing ethical concerns regarding animal welfare in scientific research. The impact of Organ-on-a-Chip technology extends beyond laboratory research, potentially speeding up the drug development process, improving drug efficacy and safety, and ultimately leading to more effective healthcare solutions.
1. High Precision in Simulating Human Physiology
Organ-on-a-chip technology offers unparalleled precision in mimicking human organ functionalities and responses. This high degree of accuracy is crucial for predictive modeling of diseases and personalized medicine, significantly improving the reliability of preclinical tests over traditional animal models.
2. Reduction in Animal Testing
One of the most ethical advantages of organ-on-a-chip is its potential to reduce, or even eliminate, the need for animal testing. By accurately replicating human organ systems, these chips can provide more relevant data directly related to human health, thereby decreasing the reliance on animal models.
3. Cost and Time Efficiency
The use of organ-on-a-chip systems can lead to substantial cost savings and reduced timeframes in drug development processes. These chips streamline the testing phase, allowing for simultaneous evaluation of multiple variables, which accelerates research and development timelines significantly.
4. Customizability for Disease Models
These microfluidic devices are highly adaptable, enabling researchers to create specific disease models on a chip. This flexibility allows for the study of disease progression and drug response in a controlled environment, providing insights that are not achievable through conventional methods.
1. Technology Compatibility
Ensure the supplier's technology is compatible with your existing laboratory equipment and research needs. Compatibility is crucial for seamless integration and efficient experimentation.
2. Customization Options
Evaluate if the supplier offers customization options for their Organ-on-a-Chip systems. Tailored solutions can significantly enhance the relevance and outcomes of your research.
3. Quality Assurance
Look for suppliers with robust quality assurance processes. High-quality chips are essential for reliable and reproducible results in your experiments.
4. Scalability
Consider the supplier's ability to scale production to meet your project's needs, whether you're conducting small-scale research or large-scale drug testing.
5. Technical Support
Assess the level of technical support and training the supplier provides. Adequate support is vital for troubleshooting and ensuring optimal use of the Organ-on-a-Chip technology.
6. Cost-effectiveness
Analyze the cost-effectiveness of their offerings. While quality should not be compromised, the supplier should offer competitive pricing and value for money.
7. Regulatory Compliance
Ensure the supplier adheres to relevant regulatory standards. Compliance is key to ensuring the safety and validity of your research findings.
Organ-on-a-chip technology is revolutionizing the pharmaceutical industry by providing a more accurate and efficient method for drug testing and development. This innovative approach allows for the simulation of human organ responses to various substances without the ethical concerns and logistical complexities of traditional animal testing. By mimicking the human body's physiological responses, companies can better predict how drugs will behave in humans, significantly reducing the time and cost associated with bringing new medications to market. In the cosmetics sector, organ-on-a-chip is emerging as a powerful tool for product safety and efficacy testing. With increasing regulatory and consumer demand for cruelty-free products, this technology offers an ethical alternative to animal testing. Companies can utilize organ-on-a-chip to assess the potential irritancy or toxicity of new products on human tissue models, ensuring they are safe for consumer use while adhering to ethical standards. The healthcare industry benefits from organ-on-a-chip through personalized medicine applications. By using patients' cells to create organ models, medical professionals can predict individual responses to drugs or treatments, tailoring healthcare solutions to the specific needs of each patient. This not only improves patient outcomes but also reduces the risk of adverse reactions, paving the way for more personalized and effective healthcare strategies. Organ-on-a-chip technology also holds promise for environmental monitoring, enabling the detection and analysis of toxins in air, water, and soil. By simulating human organ responses to environmental contaminants, researchers can better assess the potential health risks posed by pollution. This application is particularly valuable for industries involved in environmental cleanup and monitoring, offering a sophisticated tool for evaluating the impact of pollutants on human health and guiding remediation efforts.
Organ-on-a-chip technology, a groundbreaking method that simulates human organ systems on microfluidic chips for drug testing and disease modeling, is currently positioned at varying Technology Readiness Levels (TRLs) depending on the specific organ system being emulated. Generally, these technologies are at a TRL ranging from 4 to 6. This stage is characterized by the validation of the prototype's functionality in a laboratory setting, but not yet in a real-world environment. The reason for this positioning stems primarily from technical challenges related to the complexity of human organs. Replicating the intricate interplay of cells, tissues, and organs in a way that accurately mimics human physiology demands precise control over the microenvironment, including factors like fluid flow, mechanical forces, and biochemical gradients. Additionally, ensuring the chips can be produced consistently and can integrate with existing laboratory infrastructure presents significant engineering challenges. Despite these hurdles, the technology has made substantial progress, with several organ systems, such as the liver and lung, demonstrating promising results in drug efficacy and toxicity testing. The ongoing research and development efforts aim to address the remaining technical obstacles, moving organ-on-a-chip technologies closer to higher TRLs and broader application in biomedical research and personalized medicine.
In the Short-Term, advancements in organ-on-a-chip technology are expected to focus on improving the physiological relevance of these models. Enhanced microfluidics and tissue engineering techniques will allow for more accurate simulations of human organ functionalities and interactions. This phase will likely see increased adoption in pharmaceutical testing, reducing the reliance on animal models and accelerating drug discovery processes. The Mid-Term developments are anticipated to usher in integrated multi-organ systems, enabling comprehensive studies of complex biological interactions and systemic diseases. Advancements in sensor technology and data analysis will facilitate real-time monitoring of biochemical processes, offering deeper insights into organ responses to various stimuli. This period will mark a significant leap towards personalized medicine, as these systems could be customized with patient-specific cells to predict individual responses to treatments. Looking into the Long-Term, the fusion of organ-on-a-chip technology with artificial intelligence and machine learning is poised to revolutionize biomedical research and healthcare. Predictive modeling will reach new heights, allowing for the virtual simulation of organ systems and disease progression. This could lead to the development of novel therapeutic strategies and more effective, tailored treatments. Moreover, the long-term might witness the advent of fully functional, bioengineered organs for transplantation, addressing the acute shortage in organ donations and transforming transplant medicine.
